Nanoviricides - NNVC STOCK NEWS

NanoViricides (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, will present at the Global AMR Summit 2024 on October 9, 2024, in Cambridge, MA. Dr. Diwan will discuss the company's 'Trojan Horse' Platform Technology to combat antimicrobial resistance (AMR).

The technology enables delivery of 'war-heads' directly onto pathogens, potentially reducing toxicity and improving pharmacokinetics. NanoViricides' lead drug, NV-387, has completed Phase 1a/1b trials with no reported adverse events. It has shown strong antiviral activity against multiple virus families, including Coronaviruses, RSV, and Influenza A.

NV-387 could be the first single drug to treat all 'tripledemic' viral infections. The company is also developing 'dual-action' nanoviricides to potentially cure viral infections by blocking the complete Virus Life Cycle.

NanoViricides has filed its Annual Report for the fiscal year ending June 30, 2024. As of June 30, 2024, the company reported approximately $4.97 million in cash and equivalents, $7.5 million in net property and equipment, and $1.36 million in total current liabilities. The company utilized $6.31 million for operating activities, including Phase Ia/Ib clinical trials of NV-387. NanoViricides raised $3.12 million through an At-the-Market offering and an additional $1.53 million subsequently, increasing its available cash to approximately $9.5 million. Despite this, the company expressed substantial doubt about its ability to continue operations through September 2025 without additional funding. NV-387, a broad-spectrum antiviral, has shown promise in preclinical trials and is advancing to Phase II clinical trials for RSV and MPOX. The company is exploring non-dilutive funding and partnerships to support its objectives.

NanoViricides has signed a Memorandum of Understanding (MoU) with TheraCour Pharma, granting it a right of first refusal (ROFR) for all antiviral drug developments. This agreement, made on September 23, 2024, includes intellectual property rights for developing treatments against any viral infections.

The company's lead drug, NV-387, has shown promising results in animal studies against various viruses and is set to enter Phase II clinical trials for diseases like RSV, Influenza, Bird Flu, COVID, and MPOX/Smallpox. Additionally, the company has developed 'Trojan Horse' drugs that can target multiple stages of a virus's lifecycle.

This MoU allows NanoViricides to rapidly develop new antiviral drugs, even for unforeseen viruses, and negotiate licenses for specific antiviral fields. The nanoviricide technology aims to revolutionize antiviral treatments by mimicking host cells to destabilize viruses.

NanoViricides (NYSE:NNVC) is investigating the use of its drug candidate NV-387 to treat MPOX under the WHO MEURI protocol, following the recent MPOX outbreak declaration. Key points:

1. NV-387 completed Phase I trials with no adverse events reported.
2. It showed strong survival improvement in animal studies, matching the approved drug tecovirimat.
3. NV-387 was found superior or equivalent to existing drugs for RSV, Influenza, and COVID in non-clinical trials.
4. The current MPOX epidemic is caused by Clade 1/1b, which is more severe than the 2022 Clade 2 outbreak.
5. NV-387 acts via 'Re-Infection Inhibition', blocking virus cell infection.

The company believes NV-387 could be revolutionary for viral infection treatment if proven effective in human trials.

NanoViricides is progressing towards a Phase II clinical trial of its drug candidate NV-387, aimed at treating multiple viral infections including RSV, COVID, and Influenza. Dr. Anil Diwan is collaborating with experts to develop a trial plan and protocol. NV-387 has demonstrated strong effectiveness in animal studies and could potentially become a first-line treatment for respiratory viral infections, eliminating the need for testing virus types before treatment.

The estimated market size for these infections is over $8 billion in 2024, expected to grow to $12 billion by 2027. The Phase II trial will assess NV-387's effectiveness against multiple viruses in a single study, aiming to reduce costs and enhance return on investment. NV-387 recently completed a Phase I trial, showing good tolerability. The company envisions a new paradigm in treating viral infections, similar to broad-spectrum antibiotics for bacteria.

NanoViricides (NYSE:NNVC) provides an update on its clinical program for NV-387, a broad-spectrum antiviral drug. Key points:

• NV-387 mimics sulfated-proteoglycan features used by over 90% of pathogenic human viruses to infect cells
• Showed superiority or equivalence to existing drugs in animal trials against influenza, COVID, RSV, and orthopoxviruses
• Potential market size of $8 billion in 2024, growing to $12 billion in three years for influenza, RSV, and COVID alone
• Company completing database audit of Phase 1a/1b trial and preparing for Phase II trials
• Developing novel adaptive clinical trial design to evaluate effectiveness against multiple respiratory viruses
• Initiating outreach for big pharma collaborations to speed up programs and provide financing

NanoViricides, Inc. (NYSE American: NNVC) is developing NV-387, a broad-spectrum antiviral drug candidate showing promise against multiple viruses, including COVID-19, RSV, and influenza. The company recently completed a Phase 1 safety study for NV-387, with results expected in the second half of 2024. A Phase 2 clinical trial for RSV is being planned.

Key highlights:

• NV-387 demonstrated 180% improvement in survival compared to Remdesivir's 50% in animal studies
• Oral and injectable formulations developed
• Showed excellent safety and tolerability in Phase 1 human trials
• Potential to address limitations of current COVID-19 treatments
• Broad spectrum activity could represent a new paradigm in viral therapy

NanoViricides, a clinical-stage leader in antiviral nanomedicines, has gained significant attention through two independent research reports. The reports emphasize the broad-spectrum potential of NanoViricides' lead drug candidate, NV-387, which has shown efficacy in preclinical trials against multiple viruses, including RSV, Influenza A, and COVID-19. This compound could disrupt the $3 billion market for antiviral therapies. The company's transition into clinical-stage development and upcoming Phase 1 and 2 trials are key milestones. Analysts highlight the promise of NV-387 as an orally deliverable antiviral medication that could be widely prescribed, marking a potential breakthrough in treating viral respiratory infections.

NanoViricides (NYSE American:NNVC) reminds investors of the strong safety and effectiveness of its lead drug candidate NV-387 against coronaviruses. The company highlights the need for effective COVID-19 treatments, as new variants continue to emerge. Animal studies show NV-387 outperforming remdesivir, with a 180% improvement in survival rates for intravenous treatment and 88% for oral formulation.

NV-387 has completed a Phase I human clinical trial in India, demonstrating excellent safety and tolerability. The drug shows broad antiviral spectrum, potentially effective against coronaviruses, RSV, influenza, and poxviruses. NanoViricides is now seeking collaborations with pharmaceutical companies to advance NV-387 towards regulatory approvals for multiple antiviral indications.